CBIO vs PYXS
CBIO: A clinical-stage oncology biotech developing a PD-1 x VEGF bispecific antibody backbone and a portfolio of antibody-drug conjugates to treat solid tumors. PYXS: Pyxis Oncology is a clinical-stage biopharma developing innovative antibody-drug conjugates (ADCs) that target the tumor microenvironment to improve efficacy in difficult-to-treat solid tumors.
Side-by-side fundamentals
| Metric | CBIO | PYXS | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $16.93 | $2.65 | |
| Market cap as of 2026-08-03 | $629M | $168M | |
| Net margin as of 2026-08-03 | -990.3% | -574.5% | PYXS higher |
| Gross margin as of 2026-08-03 | -0.5% | +82.8% | PYXS higher |
| Operating margin as of 2026-08-03 | -978.0% | -609.2% | PYXS higher |
| ROE as of 2026-08-03 | -102.1% | -70.8% | PYXS higher |
| ROA as of 2026-08-03 | -89.3% | -49.3% | PYXS higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.00 | CBIO lower |
| Revenue growth (YoY) as of 2026-08-03 | +413.7% | -14.2% | CBIO higher |
| Beta as of 2026-08-03 | 1.24 | 1.43 | |
| 1-year return as of 2026-07-27 close | +27.4% | +136.6% | PYXS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.